Welcome to Drugdu.com
  • For Buyer
  • For Supplier
  • 中文专栏
media
  • Home
  • Ddu News
  • Newscast
  • Market Reports
  • Why Small Biotech Needs To Plan Ahead For Global Reach

    If small biotech does more to plan ahead for ex-US market requirements, companies and their investors – and crucially patients – will benefit.

    • Source: https://invivo.pharmaintelligence.informa.com/IV124998/Missed-Opportunities-Why-Small-Biotech-Needs-To-Plan-Ahead-For-Global-Reach
    • 1,113
    • April 6, 2022
    biotech commercializing
  • Suven Life Sciences Rises 1% on Patent from Mexico and New Zealand

    Neurodegenerative diseases are plenty in number, but to find the ultimate research is still ongoing worldwide. One company involved in this process is Suven Life Sciences. They have discovered novel chemical entities responsible for the treatment of neurodegenerative diseases, which were claimed for patenting.

    • Source: MoneyControl
    • 470
    • August 9, 2018
    biotech Company Insight neurodegenerative disease
  • HitGen and Merck Collaborates For DNA Library Screening

    HitGen and Merck have updated their licensing agreement to a full-fledged drug discovery collaboration in order to screen DNA-encoded libraries for new small-molecule assets.

    • Source: FierceBiotech
    • 700
    • August 8, 2018
    biotech China Company Insight Merck
  • HiFiBiO Receives New Funding, Inks R&D Deal with Takeda

    HiFiBiO Therapeutics is aspiring to work on antibody therapies for different gastrointestinal diseases, cancers and other disorders by signing a pact with Japanese Pharma and biotech company Takeda.

    • Source: FierceBiotech
    • 539
    • August 2, 2018
    biotech Company Insight Takeda
  • Electrocore Releases Gammacore Therapy against Migraine and Episodic Cluster Headaches

    ElectroCore, famous for bioelectronic medicines, is associating with UpScriptHealth to deliver its gammaCore treatment via direct-to-patient telemedicine program. This non-invasive stimulation therapy of vagus nerve is used to treat migraines and episodic cluster headaches among the adults.

    • Source: FierceBiotech
    • 586
    • July 19, 2018
    biotech cluster headache medtech migraine New Approvals
  • Spero Gets Grant of $54M for Biodefense R&D for SPR994

    Spero Therapeutics granted $15.7 million for research on SPR994, its oral carbapenem-class candidate, to study the drug’s efficacy against biological threats like anthrax, plague and melioidosis as a part of an interagency collaboration.

    • Source: FierceBiotech
    • 618
    • July 18, 2018
    biotech Company Insight
  • Biontech and Genevant Sciences Join Hands to Roll Out Rare Disease Drugs

    In a joint venture, German biopharmaceutical firm BioNTech and Genevant Sciences, a genetic disorder therapeutics maker plan to develop mRNA therapy programmes targeting rare diseases with severely deficient medical attention.

    • Source: Pharmaceutical Technology
    • 573
    • July 16, 2018
    biotech Company Insight rare diseases
  • NBE Therapeutics Receives $20 million in Series B by Novo Holdings

    Switzerland-based NBE Therapeutics AG, a biopharmaceutical company, announced a $20 million extension of series B funding led by Novo Holdings. Earlier in the series B funding round, the company had received $20 million, bringing the total funding to $40 million. The Swiss startup will use the new funding for the testing of the anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in patients with solid tumors.

    • Source: FierceBiotech
    • 522
    • June 29, 2018
    biotech cancer Company Insight
  • Carisma Therapeutics Bags $53 Million in Series A Funding led by AbbVie

    Philadelphia-based Carisma Therapeutics bagged $53 million in series A funding, led by AbbVie Ventures Co-led by HealthCap, new backers Wellington Partners, MRL Ventures Fund, TPG Biotech, and Agent Capital.

    • Source: FierceBiotech
    • 555
    • June 28, 2018
    biotech CAR-T therapies Company Insights funding
  • Biotech Crinetics Therapeutics Raises $86 million in IPO

    The San Diego-based biotech company Crinetics Therapeutics recently raised $86 million in an IPO. Prior to the new funding, the company received $63.5 million in series B funding and will see its lead asset through phase 2.

    • Source: FierceBiotech
    • 613
    • June 26, 2018
    biotech Clinical Trials endocrine disorders
1 2

Go to Page

Trending Topics

Clinical TrialsCompany InsightDdu CollegeDdu NewsExhibitions & ActivitiesMarket ReportsMarket ViewsNew ApprovalsResearches

Hot Tags

ACTDantibodyAppasthmabreast cancercancerCPhIcredit verificationEMAEUFDAinnovationmedical devicepharmaceuticaltherapyWHO

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.

Exhibitions & Activitiesmore

  • MEDICAL FAIR INDIA

    March 31, 2022
  • Zdravookhraneniye 2021 Moscow Russia

    August 26, 2021
  • CPhI China 2021

    August 26, 2021
  • FIME – 2021

    August 26, 2021
  • MEDICA & COMPAMED Düsseldorf 2021

    August 26, 2021

Market Reportsmore

  • China’s Import and Export Market Report of Vitamins

    August 26, 2021
  • 10 Triumphant Drug Launches Of The Decade

    August 26, 2021
  • The New CRISPR-Based Covid-19 Test Could Be a Game-Changer

    August 26, 2021
  • China’s Import and Export Market Report of Diabetes Drugs

    August 25, 2021
  • China’s Import and Export Market Report of Contraceptive Drugs

    August 24, 2021
  • Customer Services

  • Contact Us
  • Help Center
  • About Us

  • About Drugdu.com
  • Site Map
  • Buy on Drugdu.com

  • Browse Product Categories
  • Sell on Drugdu.com

  • Supplier Memberships
  • Request for Quotation
  • Blogroll

  • ECHEMI
  • VIETNAM MEDI-PHARM EXPO
  • MEDICARE TAIWAN
  • CPhl & P-MEC China
  • IMMEXLS

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.